Interrelationships among Lipoprotein Levels, Sex Hormones, Anthropometric Parameters, and Age in Hypogonadal Men Treated for 1 Year with a Permeation-Enhanced Testosterone Transdermal System1
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Serum lipoproteins and cardiovascular risk are affected by endogenous and exogenous sex hormones. As part of a multicenter evaluation of a permeation-enhanced testosterone transdermal system (TTD), the interrelationships among serum lipoproteins, hormone levels, anthropometric parameters, and age were investigated in 29 hypogonadal men. Subjects (aged 21-65 yr) were first studied during prior treatment with im testosterone esters (IM-T), then during an 8-week period of androgen withdrawal resulting in a hypogonadal state (HG), and finally during a 1-yr treatment period with the TTD. Compared with treatment with IM-T, the HG period produced increases in high density lipoprotein [HDL; 12.0 +/- 1.6% (+/-SEM); P<0.001] and total cholesterol (4.2 +/- 1.9%; P: = 0.02) and a decrease in the cholesterol/HDL ratio (-9.7 +/- 2.8%; P = 0.02). Compared with the HG period, TTD treatment produced decreases in HDL (-7.6 +/- 2.5%; P = 0.002) and increases in the cholesterol/HDL ratio (9.0 +/- 2.5%; P = 0.01) and triglycerides (20.7 +/- 6.4%; P: = 0.03). Small decreases in total cholesterol (-1.2 +/- 1.8%; P: = 0.1) and low density lipoprotein (-0.8 +/- 2.6%; P = 0.07) were also observed during TTD, but did not reach statistical significance. Likewise, there were no significant differences between the IM-T and TTD treatments. Serum HDL levels showed a strong negative correlation with body mass index and other obesity parameters in all three study periods (r < -0.45; P < 0.02). During treatment with TTD, serum testosterone levels also correlated negatively with body mass index (r = -0.621; P < 0.001). As a consequence of these relationships, a positive trend was observed between HDL and testosterone levels during TTD treatment (r = 0.336; P = 0.07). Interestingly, the changes in lipoprotein levels during TTD treatment indicated a more favorable profile (decrease in cholesterol and low density lipoprotein levels) with increasing age of the patients. In hypogonadal men the effects of transdermal testosterone replacement on serum lipoproteins appear consistent with the physiological effects of testosterone in eugonadal men.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men
Bhasin, S., Storer, T. W., Berman, N., Callegari, C., Clevenger, B., Phillips, J., Bunnell, T. J., Tricker, R., Shirazi, A., & Casaburi, R. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607043350101 · Cited by 1,659
High-Density Lipoprotein — The Clinical Implications of Recent Studies
Desforges, J. F., Gordon, D. J., & Rifkind, B. M. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911093211907 · Cited by 1,547
A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction.
Stampfer, M. J., Sacks, F. M., Salvini, S., Willett, W. C., & Hennekens, C. H. (1991) · New England Journal of Medicine · doi:10.1056/nejm199108083250601 · Cited by 1,163
Katznelson, L., Finkelstein, J. S., Schoenfeld, D. A., Rosenthal, D. I., Anderson, E. J., & Klibanski, A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.12.8954042 · Cited by 791 · cited 1×
“This suggests that the observed weight gain may have resulted from an increase in lean mass rather than fat mass, as seen in other testosterone replacement studies in hypogonadal men in which body composition was measured (57, 58).”
ResultTestosterone administration to elderly men increases skeletal muscle strength and protein synthesis
Urban, R. J., Bodenburg, Y. H., Gilkison, C., Foxworth, J., Coggan, A. R., Wolfe, R. R., & Ferrando, A. (1995) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1995.269.5.e820 · Cited by 608
Vermeulen, A. (1996) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.5.1821 · Cited by 455
Effects of Testosterone on Coronary Vasomotor Regulation in Men With Coronary Heart Disease
Webb, C. M., McNeill, J. G., Hayward, C. S., de Zeigler, D., & Collins, P. (1999) · Circulation · doi:10.1161/01.cir.100.16.1690 · Cited by 451 · cited 1×
“In contrast to the effects of testosterone replacement on HDL levels and cholesterol/HDL ratios, recent studies suggest that testosterone may have cardioprotective effects in men related to vasodilation (63) and other antiischemic mechanisms (64, 65), and that testosterone may be potentially beneficial as a cardiovasc…”
BackgroundLow serum testosterone and sex-hormone-binding-globulin in massively obese men
GLASS, A. R., SWERDLOFF, R. S., BRAY, G. A., DAHMS, W. T., & ATKINSON, R. L. (1977) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-45-6-1211 · Cited by 430 · cited 6×
“Mean SHBG levels increased during the HG period.”
BackgroundInfluentialAcute Anti-Ischemic Effect of Testosterone in Men With Coronary Artery Disease
Rosano, G. M. C., Leonardo, F., Pagnotta, P., Pelliccia, F., Panina, G., Cerquetani, E., della Monica, P. L., Bonfigli, B., Volpe, M., & Chierchia, S. L. (1999) · Circulation · doi:10.1161/01.cir.99.13.1666 · Cited by 367
ZUMOFF, B., STRAIN, G. W., MILLER, L. K., ROSNER, W., SENIE, R., SERES, D. S., & ROSENFELD, R. S. (1990) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-71-4-929 · Cited by 349
Vermeulen, A. (1993) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.76.5.1140 · Cited by 346
Pathogenesis of the decreased androgen levels in obese men.
Giagulli, V. A., Kaufman, J. M., & Vermeulen, A. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.79.4.7962311 · Cited by 215 · cited 2×
“In obese men with intact hypothalamic-pituitary-gonadal axes, the increase in E2/T ratio and the negative feedback effects of circulating E2 levels on LH secretion (51, 52) could be important factors in the development of hypogonadotropic hypogonadism (48).”
BackgroundWayne Meikle, A., Arver, S., Dobs, A. S., Adolfsson, J., Sanders, S. W., Middleton, R. G., Stephenson, R. A., Hoover, D. R., Rajaram, L., & Mazer, N. A. (1997) · Urology · doi:10.1016/s0090-4295(96)00445-1 · Cited by 125
Self-citation
Cited by
Wang, C., Cunningham, G., Dobs, A., Iranmanesh, A., Matsumoto, A. M., Snyder, P. J., Weber, T., Berman, N., Hull, L., & Swerdloff, R. S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032006 · Cited by 656
“The number of subjects with high hemoglobin or hematocrit that required discontinuation was similar to other reports (23, 34, 35).”
ResultSelf-citationAndrogens and Coronary Artery Disease
Wu, F. C. W., & von Eckardstein, A. (2003) · Endocrine Reviews · doi:10.1210/er.2001-0025 · Cited by 592
Andropause: clinical implications of the decline in serum testosterone levels with aging in men
Matsumoto, A. M. (2002) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/57.2.m76 · Cited by 490
Hypogonadism in men consuming sustained-action oral opioids
Daniell, H. W. (2002) · The Journal of Pain · doi:10.1054/jpai.2002.126790 · Cited by 401
Bhasin, S., Calof, O. M., Storer, T. W., Lee, M. L., Mazer, N. A., Jasuja, R., Montori, V. M., Gao, W., & Dalton, J. T. (2006) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0120 · Cited by 300
Self-citation
Metadata
- Authors
- Dobs, A. S., Bachorik, P. S., Arver, S., Meikle, A. W., Sanders, S. W., Caramelli, K. E., & Mazer, N. A.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2001-03-01
- Volume
- 86
- Issue
- 3
- Pages
- 1026-1033
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1996162226
- Cited by
- 73
- References
- 13
- FWCI
- 3.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.